Haemophilia Trial, Recruiting (NCT02207894)

Haemophilia Trial, Recruiting NCT02207894 Sponsor: Haemophilia Centre Rhine Main Condition: Haemophilia

Printed from Voxsanity (voxsanity.com.au) — NCT02207894 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Haemophilia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

You are male, at any age, and have been diagnosed with haemophilia A (a condition where the blood does not clot properly due to low levels of a protein called Factor VIII).
Your haemophilia A is classified as severe, moderate, or mild based on your Factor VIII levels (as measured by your doctor).
Your doctor has detected a substance in your blood called an "inhibitor" at a level above 0.6 BU, which means your body is fighting against the treatment used to manage your condition.
Alternatively, even if your inhibitor level is below 0.6 BU, your Factor VIII treatment is not lasting as long or working as well as expected (confirm with trial site).
You have previously tried a treatment to remove inhibitors (called immune tolerance induction) that did not work, and you are still welcome to apply.

Who may not be able to join:

You are female.

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Carmen Escuriola Ettingshausen, MD, Director HZRM

Phone: +49 (0) 15115511159

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT02207894

Sponsor: Haemophilia Centre Rhine Main

Phase: Not Applicable

Status: Recruiting

Condition: Haemophilia

Trial contact: +49 (0) 15115511159

More information: https://clinicaltrials.gov/study/NCT02207894

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

"Who might be able to join this trial:

You are male, at any age, and have been diagnosed with haemophilia A (a condition where the blood does not clot properly due to low levels of a protein called Factor VIII).
Your haemophilia A is classified as severe, moderate, or mild based on your Factor VIII levels (as measured by your doctor).
Your doctor has detected a substance in your blood called an "inhibitor" at a level above 0.6 BU, which means your body is fighting against the treatment used to manage your condition.
Alternatively, even if your inhibitor level is below 0.6 BU, your Factor VIII treatment is not lasting as long or working as well as expected (confirm with trial site).
You have previously tried a treatment to remove inhibitors (called immune tolerance induction) that did not work, and you are still welcome to apply.

Who may not be able to join:

You are female.

Important: Always verify eligibility with the trial site directly before applying."

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Haemophilia Centre Rhine Main

Registry

ClinicalTrials.gov

Start date

1 August 2006

Est. completion

1 December 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

The efficacy of ITI, the primary endpoint of this observation, is defined according to the following criteria (The measure is a composite).: Inhibitor titre <0.6 BU, Incremental recovery of FVIII in the normal range,Half-life of FVIII > 7 hours.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov